QFM-BioPred: Quantum Fusion Model for Bioactivity Prediction in Cardiovascular Disease Drug Discovery

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, highlighting the urgent need for more effective treatments. The conventional drug discovery process is time-consuming and expensive; therefore, new approaches are required. Quantum machine learning in compound bioactivity prediction has been demonstrated in drug discovery, but its application in cardiovascular medicine remains limited. Therefore, this work proposed the quantum fusion model (QFM) to enhance the bioactivity predictions for heart disease treatments. The proposed model encoded molecular data into quantum states using the quantum random forest method on the ChEMBL dataset. Logistic regression classifiers were then trained on these encoded data. The QFM, which integrates quantum-inspired algorithms with classical machine learning, achieved an accuracy of 92.7% in classifying bioactive compounds, outperforming individual models and existing methods. It also demonstrated strong precision (0.92), recall (0.93), and F1 score of 0.92, with receiver operating characteristic area under the curve (AUC) and precision-recall AUC values of 0.961 and 0.959, respectively. These results indicate the model’s ability to identify complex molecular structures accurately. This work advances bioactivity prediction to aid drug development for CVDs and aligns with the United Nations Sustainable Development Goal 3: Good Health and Well-being. Future research will apply this approach to other diseases and incorporate more complex quantum circuits to enhance accuracy further. Received: 31 December 2024 | Revised: 12 May 2025 | Accepted: 30 May 2025 Conflicts of Interest The authors declare that they have no conflicts of interest to this work. Data Availability Statement The data that support the findings of this study are openly available at https://www.ebi.ac.uk. Author Contribution Statement Gundala Pallavi: Methodology, Software, Data curation, Writing – original draft, Visualization, Project administration. Ali Altalbe: Investigation, Writing – review & editing. Prasanna Kumar Rangarajan: Conceptualization, Validation, Formal analysis, Resources, Writing – review and editing, Supervision.

Authors

Institutions

Publication Details

Journal
Journal of Computational and Cognitive Engineering
Published
2025-09-01
DOI
https://doi.org/10.47852/bonviewjcce52025138
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

QFM-BioPred: Quantum Fusion Model for Bioactivity Prediction in Cardiovascular Disease Drug Discovery

Prasanna Kumar R, Ali Altalbe, Gundala Pallavi
Journal of Computational and Cognitive Engineering
Computational Drug Discovery Methods
article

QFM-BioPred: Quantum Fusion Model for Bioactivity Prediction in Cardiovascular Disease Drug Discovery

Prasanna Kumar R, Ali Altalbe, Gundala Pallavi
article en

Abstract

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, highlighting the urgent need for more effective treatments. The conventional drug discovery process is time-consuming and expensive; therefore, new approaches are required. Quantum machine learning in compound bioactivity prediction has been demonstrated in drug discovery, but its application in cardiovascular medicine remains limited. Therefore, this work proposed the quantum fusion model (QFM) to enhance the bioactivity predictions for heart disease treatments. The proposed model encoded molecular data into quantum states using the quantum random forest method on the ChEMBL dataset. Logistic regression classifiers were then trained on these encoded data. The QFM, which integrates quantum-inspired algorithms with classical machine learning, achieved an accuracy of 92.7% in classifying bioactive compounds, outperforming individual models and existing methods. It also demonstrated strong precision (0.92), recall (0.93), and F1 score of 0.92, with receiver operating characteristic area under the curve (AUC) and precision-recall AUC values of 0.961 and 0.959, respectively. These results indicate the model’s ability to identify complex molecular structures accurately. This work advances bioactivity prediction to aid drug development for CVDs and aligns with the United Nations Sustainable Development Goal 3: Good Health and Well-being. Future research will apply this approach to other diseases and incorporate more complex quantum circuits to enhance accuracy further. Received: 31 December 2024 | Revised: 12 May 2025 | Accepted: 30 May 2025 Conflicts of Interest The authors declare that they have no conflicts of interest to this work. Data Availability Statement The data that support the findings of this study are openly available at https://www.ebi.ac.uk. Author Contribution Statement Gundala Pallavi: Methodology, Software, Data curation, Writing – original draft, Visualization, Project administration. Ali Altalbe: Investigation, Writing – review & editing. Prasanna Kumar Rangarajan: Conceptualization, Validation, Formal analysis, Resources, Writing – review and editing, Supervision.

Journal of Computational and Cognitive Engineering
King Abdulaziz University (SA), Amrita Vishwa Vidyapeetham (IN)
Openalex Percentile: Top 76%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.